Geri
Pharma Mar, S.A. (PHMMF) Kazanmak
PHMMF Hisse Senedi Fiyat Grafiği
PHMMF Kazanmak
Pharma Mar, S.A.
$92.19
0%
$0
Kapanışta: Mar 27, 16:00:00 GMT-4
$92.19
0%
$0
Sonrası Piyasa: Mar 27, 20:00:00 GMT-4
Earnings FAQ
PHMMF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Pharma Mar, S.A. PHMMF'ün son çeyrekteki geliri nasıl performans gösterdi?
Pharma Mar, S.A.'in gelir tahmini nedir?
Pharma Mar, S.A.'in kazanç kalite puanı nedir?
Pharma Mar, S.A. kazançlarını ne zaman rapor eder?
Pharma Mar, S.A.'in beklenen kazançları nelerdir?
Pharma Mar, S.A. kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$92.19
Açılış fiyatı
$92.19
Günün Aralığı
$92.19 - $92.19
52 haftalık aralık
$80.91 - $110.4
İşlem hacmi
3.7K
Ort.Hacim
74
Dividend yield
--
EPS (TTM)
4.98
Piyasa Değeri
$1.5B
PHARMA MAR SA nedir?
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 505 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
Özellikler
Kaynaklar
© 2026 Finture Development Limited. Tüm hakları saklıdır.